Dasatinib
- PDF / 169,585 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 53 Downloads / 135 Views
1 S
Hepatic toxicity: case report A 57-year-old man developed hepatic toxicity during treatment with dasatinib for acute myeloid leukaemia (AML). The man, who diagnosed with BCR-ABL1 transcript AML, received treatment with various medications. Thereafter, he started receiving dasatinib 140mg daily [route not stated]. However, he developed grade III hepatic toxicity [time to reaction onset and outcome not stated]. The man’s therapy with dasatinib was discontinued after 10 days due to persistent hepatic toxicity. Later on, he received ponatinib, methotrexate and cytarabine. Additionally, he was initiated on azacitidine [5-azacitidine] along with venetoclax. Two months later, his azacitidine and venetoclax therapy was discontinued due to invasive fungal rhino-sinusitis [aetiology not stated], which was treated with isavuconazole and unspecified broad-spectrum antimicrobial agents. Later, he was re-started on venetoclax and continued on fungal prophylaxis with isavuconazole and unspecified antifungal agent. Eventually, an improvement in his clinical condition was noted. Levato L, et al. Sustained Complete Remission with Incomplete Hematologic Recovery (CRi) in a Patient with Relapsed AML and Concurrent BCR-ABL1 and CBFB Rearrangement Treated with a Combination of Venetoclax and 5-Azacytidine. Chemotherapy (Basel) 65: 51-53, No. 1, Sep 2020. Available from: URL: http:// 803519594 doi.org/10.1159/000508658
0114-9954/20/1833-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 5 Dec 2020 No. 1833
Data Loading...
